Collegium Pharmaceutical (COLL) to Release Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Collegium Pharmaceutical to post earnings of $2.20 per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Collegium Pharmaceutical Stock Up 0.7%

Shares of NASDAQ COLL opened at $45.17 on Wednesday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The stock’s 50-day simple moving average is $46.81 and its 200-day simple moving average is $41.95. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of 28.06 and a beta of 0.64.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Barclays cut their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research report on Friday, January 9th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, February 10th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Needham & Company LLC upped their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $53.40.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 17,600 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the sale, the executive vice president directly owned 103,613 shares in the company, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $47.03, for a total value of $171,659.50. Following the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. 2.51% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the company. Group One Trading LLC bought a new position in shares of Collegium Pharmaceutical in the fourth quarter worth $28,000. Kemnay Advisory Services Inc. bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth $61,000. EverSource Wealth Advisors LLC grew its holdings in Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after acquiring an additional 2,190 shares during the period. Federated Hermes Inc. raised its holdings in shares of Collegium Pharmaceutical by 225.3% in the 4th quarter. Federated Hermes Inc. now owns 2,837 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 1,965 shares in the last quarter. Finally, NewEdge Advisors LLC grew its position in Collegium Pharmaceutical by 304.6% in the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 2,294 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.